![logo](/logos/PVCT.webp)
Provectus Biopharmaceuticals, Inc.
OTC:PVCT
0.13 (USD) • At close November 27, 2023
Overzicht | Financiële gegevens
Bedrijfsnaam | Provectus Biopharmaceuticals, Inc. |
Symbool | PVCT |
Munteenheid | USD |
Prijs | 0.149 |
Beurswaarde | 62,550,728 |
Dividendpercentage | 0% |
52-weken bereik | 0.052 - 0.19 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Eric A. Wachter |
Website | https://www.provectusbio.com |
An error occurred while fetching data.
Over Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. It develops PV-10, an investigational autolytic cancer immunotherapy for adult solid tumor cancers, such as melanoma and gastrointestinal tumors, including hepatocellular carcinoma; colorectal cancer metastatic to the liver; neuroendocrine tumors metastatic to the liver;
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)